No prior studies have investigated the effects of dietary cholesterol oxidation products (oxysterols) on atherosclerotic plaque destabilization and rupture. We used an atherosclerotic mouse model with histological features similar to those seen in ruptured human plaques to test the hypothesis that (1) dietary oxysterols accelerate plaque destabilization and rupture and (2) a NPC1L1 inhibitor, ezetimibe, has therapeutic effects on these processes. 
Introduction
There is strong evidence that oxidized lipopro-teins are atherogenic and play a key role in the pathogenesis of atherosclerotic vascular diseases [1] [2] [3] . Lowdensity lipoprotein (LDL) and other lipoproteins can be oxidized in atherosclerotic lesions or in the circulation [1] [2] [3] . Recent studies have raised the possibility that the levels of cholesterol oxidation products (oxysterols) in the diet may also be a risk factor for atherosclerosis and related vascular diseases. Oxysterols are known to be generated in food containing cholesterol (e.g., meats, eggs, and butter) by processing, cooking (deep-. In brief, cholesterol powder was placed on a cooking plate that was placed in a 200 ℃ gas oven and heated for 2 to 4 hours twice. The contents of the plate were re-dissolved in ether, and the composition of cholesterol oxidation products was analyzed by gas-liquid chromatography 23) . The following oxysterol products were present in the following amounts by weight percentage: cholesterol, 68; 7α-hydroxycholesterol, 3.7; 7β-hydroxycholesterol, 4.3; 5β-epoxycholesterol, 3.9; 5α-epoxycholesterol, 0.5; cholestanetriol, 1.6; 7-ketocholesterol, 4.4; and identified oxysterols, 13. Unidentified oxysterols comprised more than ten unknown peaks.
A high-fat diet (HFD) containing 21% fat from lard and supplemented with 0.15% (wt/wt) pure cholesterol (Oriental Yeast) was prepared according to the formula recommended by the American Institute of Nutrition. The diet contained the following constituents: casein, cystine, corn starch, sucrose, cholic acid, mineral mixture, vitamin mixture, powdered cellulose, choline bitartrate, and tert-butylhydroquinone.
In addition, an HFD containing oxysterols (oxyfrying/heating) or prolonged storage in the presence of oxygen from the air 4) ; therefore, relatively high levels of oxysterols (5-10% of the cholesterol content is oxidized) are found in typical cholesterol-rich Western diets, such as in fast foods 5) . Studies in animals and humans have reported that oxysterols from the diet are absorbed by the small intestine, incorporated into chylomicrons and LDL 6) , and detected at higher levels in atherosclerotic lesions than in the circulation 7) . Staprans et al. 8, 9) have shown that the addition of oxysterols to the diet increases the severity of fatty streak lesions in the aorta in mouse and rabbit models of atherosclerosis.
Atherosclerotic plaque destabilization and rupture with vascular occlusive thrombosis is the most common cause of myocardial infarction in humans 2, 3, 10, 11) , and non-occlusive plaque rupture may stimulate the progression of arterial stenosis; however, the molecular and cellular mechanisms behind plaque rupture remain poorly understood. Acquisition of a mechanistic understanding of plaque rupture could lead to the development of drugs that prevent or delay plaque rupture. Investigation of the mechanisms underlying the development of aortic atherosclerosis in animals may not necessarily reveal the mechanistic link to plaque destabilization and rupture because aortic atherosclerotic lesions in many animal models do not progress to plaque rupture spontaneously. No prior studies have investigated whether dietary oxysterols enhance plaque destabilization and rupture.
Ezetimibe, an inhibitor of the cholesterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein 12) , inhibits the absorption of both dietary cholesterol and oxysterols in animals and humans 13) , and thereby the development of aortic atherosclerosis induced by a regular Western diet containing pure cholesterol in animals 14, 15) . Prior studies, however, have not addressed the therapeutic effects of ezetimibe on atherosclerotic plaque development, destabilization and rupture induced by dietary oxysterols.
In the present study, we tested the hypothesis that dietary oxysterols accelerate atherosclerotic plaque destabilization and rupture. To test this hypothesis, we analyzed advanced brachiocephalic artery plaques in ApoE −/− mice that have histological features similar to those in ruptured human plaques [16] [17] [18] [19] [20] . To elucidate the mechanism behind dietary oxysterol-induced plaque destabilization and rupture, we performed mechanistic analyses of the plaques and documented that dietary oxysterols enhance monocyte infiltration/ activation and MMP activity via the MCP-1-CCR2 pathway. We also tested the hypothesis that reducing the absorption of oxysterols by treatment with ezeti-blocked by incubation with 0.3% H2O2 in methanol for 10 minutes. For antigen retrieval, sections were boiled for 20 minutes in citrate buffer (pH 6.0). After blocking with 3% skim milk, sections were incubated overnight at 4 ℃ with the anti-mouse macrophage antibody (Mac-3; dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-mouse MCP-1 antibody (dilution 1:200; Santa Cruz Biotechnology) followed by incubation with biotin-conjugated secondary antibodies. The sections were then washed and treated with avidin-biotin-peroxidase complexes. The sections were incubated with diaminobenzidine (DAB; Wako Pure Chemical, Osaka, Japan), and the nuclei were counterstained with hematoxylin.
Fibrous cap thickness was determined at the thinnest part of the cap by computerized image analysis. Plaque lipid core area was determined by digitally processing color images of HE-stained sections into monochrome, causing the tissue to be rendered as black and delipidated areas to appear as white. The total white area in the plaque was expressed as a percentage of the total plaque area to give the fractional lipid content. The Mac-3-and MCP-1-positive areas in atherosclerotic plaque were measured.
In the other sets of experiments, brachiocephalic arteries were embedded in OCT compound (Sakura Finetech) and subjected to cryosectioning (6 μm) using 7-KC and ApoB48 immunostaining and in situ zymography. 7-KC immunohistochemistry was performed using a Histofine mouse stain kit (Nichirei Biosciences). Sections were incubated with the antimouse 7-ketocholesterol antibody (dilution 1:100; Nikken Seil Corporation, Fukuroi, Japan). For apolipoprotein B48 immunostaining, the frozen sections were incubated with 0.3% H2O2 in PBS for 10 minutes to inhibit endogenous peroxidase activity. After blocking with 3% skim milk, sections were incubated overnight at 4 ℃ with HUC 20 IgY, which recognizes mouse ApoB48 25) , followed by incubation with peroxidase-conjugated goat anti-chicken IgG (KPL). The 7-KC-and ApoB48-positive areas in atherosclerotic plaque were measured.
A single observer who was blinded to the experimental protocol performed quantitative analysis. All images were captured with a Nikon microscope equipped with a digital camera (HC-2500) and were analyzed using Adobe Photoshop 6.0 (Adobe Systems) and Scion Image 1.62 for Windows (Scion) software.
In Situ Zymography
Gelatinase (MMP-2/gelatinase-A and MMP-9/ gelatinase-B) activity was measured in unfixed frozen sections (6μm thick) using quenched fluoresceinsterol-HFD) was prepared by adding oxysterols to the HFD at the expense of cholesterol. The oxysterol-HFD was identical to the HFD except that 6.8% of the added cholesterol consisted of oxysterols. Both HFD and oxysterol-HFD were stored at 4 ℃ to prevent the auto-oxidation of cholesterol.
Experimental Protocol
Starting at 18 weeks of age, ApoE −/− mice were divided into 2 groups, one to receive HFD, the other oxysterol-HFD. After 4 weeks on the experimental diets, all mice received angiotensin Ⅱ (1.9 mg/kg per day) for 4 weeks 22, 24) . Angiotensin Ⅱ was dissolved in phosphate-buffered saline and loaded into miniosmotic pumps (Alzet, Cupertino, CA) according to the recommendations of the manufacturer. These pumps, containing angiotensin Ⅱ, were placed intraperitoneally via a mid-scapular incision in mice under deep anesthesia with ketamine/xylazine (50 mg/kg and 1 mg/kg), the latter administered intraperitoneally.
At the start of the angiotensin Ⅱ infusion, the HFD-and oxysterol-HFD-fed groups were further divided into the following four sub-groups: (1) control HFD-vehicle group that received oral administration of 0.5% carboxy methyl cellulose and (2) control HFD treated with ezetimibe group that was treated orally with ezetimibe at 5 mg/kg per day dissolved in 0.5% carboxy methyl cellulose for 4 weeks. (3) oxysterol HFD-vehicle group (4) oxysterol HFD treated with ezetimibe group. The dose of ezetimibe used in this study was selected because of the effectiveness reported in prior studies 14, 15) . Systolic blood pressure and heart rate were measured by the tail-cuff method before and 4 weeks after angiotensin Ⅱ infusion.
Blood samples were collected for analysis from the left ventricle 1 or 4 weeks after angiotensin Ⅱ infusion. Brachiocephalic arteries were isolated with a piece of the aortic arch and fixed in 10% buffered formalin for histological and immunohistochemical analyses.
Histopathology, Plaque Morphometry, and Immunohistochemistry
Brachiocephalic arteries were embedded in paraffin. Six sets of serial sections obtained at 30 μm intervals (starting from the proximal end of brachiocephalic artery) were stained with hematoxylin-eosin (HE) or Elastica van Gieson (EVG) to measure the incidence of plaque rupture, fibrous cap thickness and lipid core area, as previously described [16] [17] [18] [19] . The average of the 6 images was reported for each animal. Moreover, serial brachiocephalic arterial sections were deparaffinized, and endogenous peroxidase was lary ULBON HR-1 column (0.25 mm×50 m) with a liquid-phase thickness of 0.25 mm; oven temperature, 270 ℃; injector temperature, 300 ℃; flow rate of helium, 0.7 mL/min; split ratio 1:50; make-up gas (helium), 40.1 mL/min. The mass spectra were measured within a mass range of m/z 50-600. The scan speed was one scan per second. The ionization energy was 70 eV.
Experimental Protocol using ApoE
−/− CCR2 −/−
Double Knockout Mice
To determine the primary role of oxysterol-mediated inflammation via MCP-1-CCR2 pathway in plaque destabilization and rupture, ApoE
−/− mice were divided into 2 groups, one to receive HFD and the other oxysterol-HFD, as in the above experimental protocol, to examine the characteristics of brachiocephalic arteries, the lipid profile and flow cytometry.
Statistical Analysis
Data are expressed as the mean±SEM. Data were analyzed using the Prism software program (GraphPad Software). Statistical analysis was assessed by two-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc multiple comparison tests. Statistical comparison between two groups was evaluated by unpaired-t test. P ＜0.05 was considered significant.
Results

Serum Lipid Levels
There were no significant changes in serum cholesterol and other lipid parameters between Apo-E −/− mice fed an HFD and those fed an oxysterol-HFD ( Table 1) . Treatment with ezetimibe significantly decreased total serum cholesterol, chylomicron, VLDL cholesterol, and LDL cholesterol levels and increased HDL cholesterol levels.
No significant changes in serum oxidized LDL/ cholesterol levels were observed between the HFD and oxysterol-HFD-fed groups ( Table 1) . Treatment with ezetimibe had no effect on serum oxidized LDL/cholesterol levels ( Table 1) .
There was no significant difference in body weight, heart rate or systolic blood pressure at weeks 0, 4, and 8 among the 4 groups ( Table 2) . Systolic blood pressure increased after angiotensin Ⅱ infusion (week 8).
Plasma Lipid Peroxides
To examine whether oxysterol-HFD increases systemic oxidative stress, plasma lipid peroxide levels were measured ( Table 3) . There was no significant difference in lipid peroxide levels between the HFD and labeled gelatinase substrate (DQ gelatin; Invitrogen) 26) . The fluorescent area produced by proteolytic digestion of quenched fluorescein-labeled gelatin was recognized as combined gelatinase activity (MMP-2＋ MMP-9). The brachiocephalic artery sections were incubated at 37 ℃ for 30 minutes according to the manufacturer's protocol. Fluorescent microscopy (Olympus BX50) was used to detect gelatinase activity as green fluorescence. Negative control zymograms were incubated in the presence of 5 mM EDTA. The specific removal of essential divalent cations resulted in no detectable gelatinolytic activity.
Measurement of Blood Lipoprotein Profiles and Oxidative Stress
Serum total cholesterol and lipoprotein profiles (chylomicron, LDL-cholesterol, HDL-cholesterol and VLDL-cholesterol) were measured using an HPLC system with two tandem gel-permeation columns (Skylight Biotech, Akita, Japan) 27) . To measure serum oxidized LDL levels, serum levels of lectin-like oxidized LDL receptor-1 (LOX-1) ligand were determined using a sandwich enzymelinked immunosorbent assay (ELISA), as described previously 28) . Serum LOX-1 ligand concentration was normalized to serum total cholesterol concentration (Cholesterol E-test; Wako Pure Chemical). Plasma concentrations of thiobarbituric acid reactive substances (TBARs) were determined as previously described 29) .
Flowcytometry
Peripheral blood was drawn via cardiac puncture, and red blood cells were lysed with VersaLyse lysing solution (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) for 10 minutes at room temperature. Cells were incubated with a cocktail of mAb against CD115-PE (BD Pharmingen), CD11b-APC (BD Pharmingen) and Ly-6C-FITC (eBioscience) or appropriate isotype controls (BD Pharmingen) for 30 minutes at 4 ℃, followed by blocking Fc Receptor with anti-CD 16/32 mAb (BD Pharmingen) for 5 minutes at 4 ℃, and analyzed on a FACSCalibur (Becton Dickinson Biosciences). Monocyte subsets were identified as either Ly-6C hi CD11b hi CD115 hi or Ly-6C lo CD11b hi CD115 hi , as previously described 30) .
Identification of Oxysterols in the Plasma and Liver
Gas-liquid chromatography mass spectrometry (GCMS-QP5050A mass spectrometer and GC-17 gas chromatograph; Shimazu) was performed to measure oxysterol levels in the plasma and liver 23) . Measurement conditions were as follows: a fused silica capil- Data are expressed as the mean±SEM (n = 5). Data were compared using two-way ANOVA followed by Bonferroni's multiple comparison tests. observed in plasma oxysterol levels among the 4 groups ( Table 5) .
Atherosclerotic Plaque Destabilization and Rupture in the Brachiocephalic Artery
Histopathological and immunohistochemical analyses of plaques in the brachiocephalic artery were performed to examine atherosclerotic plaque destabilization markers (lipid core area, fibrous cap thinning, and Mac-3-positive area) ( Table 6 ). The presence of dietary oxysterols did not alter fibrous cap thickness but increased the lipid core area, mac-3-positive area, and plaque area. These changes in plaque destabilization markers were associated with increased MCP-1-positive areas. The number of disrupted/buried fibrous caps, a histopathological feature of plaque rupture, was then examined (Fig. 1A and 1B) . Feeding mice with oxysterol-HFD increased the incidence of plaque oxysterol-HFD-fed groups at week 4 (before Ang Ⅱ infusion). At week 5 (1 week after Ang Ⅱ infusion), plasma lipid peroxide levels were greater in the oxysterol-HFD-fed group than in the HFD-fed group. This difference became insignificant at week 8 (4 weeks after Ang II infusion). Treatment with ezetimibe significantly reduced lipid peroxide levels in both the HFD-and oxysterol-HFD-fed groups.
Oxysterol Levels in Plasma and Liver
Total oxysterol concentrations tended to increase in the livers of mice in the oxysterol-HFD-fed group compared to those in the HFD-fed group (Table 4) . When the ratio of total oxysterols to cholesterol was examined, the ratio was higher in the oxysterol-HFDfed group than in the HFD-fed group. Treatment with ezetimibe inhibited such an increase in the total oxysterol/cholesterol ratio. No significant changes were Fig. 2) . This monocytosis was associated with an increase in Ly6C hi subsets, but not with increases in Ly6C lo subsets. Treatment with ezetimibe prevented monocytosis of the Ly6C hi subsets induced by oxysterol-HFD.
Immunohistochemical Analysis of 7-Ketocholesterol and ApoB48
Immunohistochemical analysis showed the presence of 7-ketocholesterol (a representative oxysterol derived from diet) in brachiocephalic artery plaques (Fig. 3) . Quantitative analysis revealed an increase in 7-ketocholesterol-positive areas in the oxysterol-HFDfed group and treatment with ezetimibe inhibited this increase. Serial sections of brachiocephalic artery plaques were immunostained with antibodies for either 7-ketocholesterol or ApoB48 (a lipoprotein synthesized in the small intestine, incorporated into chylomicrons, and essential for intestinal lipid absorption) (Fig. 3C) . Interestingly, 7-ketocholesterol-positive areas colocalized with ApoB48-positive areas.
rupture compared with the HFD-vehicle-fed group.
Treatment with ezetimibe prevented the oxysterol-HFD-induced increase in plaque destabilization markers (i.e., lipid core area, monocyte area, plaque size) and rupture. Treatment with ezetimibe also increased fibrous cap thickness in both the HFD-and oxysterol-HFD-fed groups.
In Situ Zymography
Analysis of gelatinase activity, reflecting the combined activity of MMP-2 and MMP-9, by in situ zymography showed enhanced gelatinase activity in areas of monocyte/macrophage infiltration. Treatment with ezetimibe inhibited increased gelatinase activity in the oxysterol-HFD-fed group (Fig. 1C and 1D) .
Flow Cytometric Analysis of Blood Monocyte Subsets
The monocyte Ly6C hi subset is reported to play a critical role in atherosclerotic plaque progression in mice 30, 31) . Oxysterol-HFD feeding increased the num- 
CD11b
＋ monocytes. Data are reported as the mean±SEM (n = 5 to 9). Data were compared using 2-way ANOVA followed by Bonferroni's multiple comparison tests. This model is used because, unlike other models of aortic atherosclerosis, brachiocephalic artery plaques represent several key histological features of ruptured human plaques, including an increase in plaque destabilization markers (monocyte infiltration/activation, lipid accumulation, fibrous cap thinning due to decreased smooth muscle content) and evidence of disrupted/buried fibrous caps [16] [17] [18] [19] ; however, this model has been criticized because it does not display other histological features of human plaque rupture including occlusive thrombosis [16] [17] [18] [19] , which is thought to be a reflection of differences in the coagulation and thrombolytic systems between the 2 species. In addition, the incidence of rupture in this original hyperlipidemic mouse model is too infrequent (10-20% without HFD feeding 18) and 40-60% per plaque after HFD feeding 17) ) to allow for mechanistic examina- 
CCR2
−/− mice were used 22) . In ApoE −/− CCR2 −/− mice, oxysterol-HFD feeding did not induce plaque destabilization and rupture in brachiocephalic artery plaques (Fig. 4A, 4B and Table 7 ). In addition, double-knockout mice did not display an increase in monocyte infiltration, MCP-1 expression, and systemic monocytosis of Ly6C hi monocyte subsets at week 8 ( Fig. 4C  and 4D ). There was no difference in serum cholesterol levels between HFD and oxysterol-HFD groups ( Table 7) .
Discussion
Hyperlipidemic mice with advanced atherosclerotic brachiocephalic artery plaques appear to be a We report here for the first time that oxysterol-HFD feeding does not affect plasma lipid levels but enhances plaque destabilization and rupture. Mechanistic analyses of the plaques showed that oxysterol-HFD increased the infiltration of monocytes/macrophages, MCP-1 expression, and lipid core size in the plaques. Monocytosis associated with an increase in the Ly6c hi monocyte subset in circulating blood was also noted in the oxysterol-HFD-fed group. Importantly, monocyte activation and other pathogenetic features seen in plaques in ApoE −/− mice fed oxysterol-HFD were blunted in ApoE
−/− mice fed oxysterol-HFD. Accumulating evidence in humans and animals indicates that activated monocytes/macrophages play a key role in causing plaque destabilization and rupture by secreting MMP-9/gelatinase-B and MMP-2/gelatinase-A, which break down the tions and analysis of the effects of new modalities that inhibit plaque destabilization and rupture. In a previous study that examined the therapeutic effects of anti-atherosclerotic drugs 17) , an excess of 60 animals was needed per group to ensure that the studies were adequately powered. To overcome this problem, we performed chronic infusion of angiotensin Ⅱ in addition to HFD feeding in ApoE −/− mice because this has been used to enhance the features of atherogenesis, such as monocyte-mediated inflammation, lipid accumulation, and MMP activation 22, 24) . We found that chronic angiotensin Ⅱ infusion could increase the incidence of plaque rupture from less than 1 rupture per plaque (authors' unpublished observation) to 3.4 per plaque (Fig. 1A and 1B) ; therefore, in the present study, we used this modified model to investigate whether dietary oxysterols accelerate plaque rupture and whether ezetimibe has therapeutic effects on ath- It is likely that these observed therapeutic effects resulted largely from the lipid-lowering effects of ezetimibe, which markedly decreases LDL cholesterol, chylomicron, and VLDL cholesterol levels and increases HDL cholesterol levels, as reported in patients with dyslipidemia. Ezetimibe also inhibited oxysterol accumulation in the liver and plaques, monocyte infiltration/ activation, and MMP activity. The latter therapeutic effects might not necessarily be totally explained by the lipid-lowering effects of ezetimibe treatment; rather, they may result partly from a unique effect of ezetimibe, such as inhibition of dietary oxysterol absorption in the small intestine and reduced accumulation of oxysterols in atherosclerotic plaques, which can prevent plaque destabilization and rupture. These data suggest that ezetimibe could be a new therapeutic modality for subjects who overindulge in oxysterolrich Western food and in patients at high risk for cardiovascular disease owing to high plasma oxysterol levels. Because Western diets have become prevalent in non-Western countries in this era of global civilization, the quantity of oxysterols consumed in the diet is of clinically importance for the paradigm shift in the pathogenesis of atherosclerotic vascular diseases. These data indicate a primary role for monocyte infiltration/activation via the MCP-1-CCR2 pathway and the resultant increase in combined gelatinase activity (MMP-2＋MMP-9) in plaque destabilization and rupture induced by dietary oxysterols in this model. These data suggest a mechanism that connects dietary oxysterols with the pathogenesis of plaque destabilization and rupture. Our results also suggest that inhibiting the absorption of dietary oxysterols with ezetimibe may be a useful treatment for high-risk patients with increased dietary oxysterol intake or whose plasma oxysterol concentrations are elevated. extracellular matrix (a determinant of the integrity of fibrous caps) 3, 32) . Gough et al. 18) reported that macrophage-targeted expression of a constitutively active MMP-9 mutant resulted in increased incidence of plaque rupture in advanced brachiocephalic artery plaques of ApoE −/− mice. Clinical studies have shown a correlation between MMP-9 and MMP-2 and cardiovascular events in patients with acute coronary syndrome 33, 34) ; therefore, we examined gelatinase activity using in situ zymography and found enhanced gelatinase activity in areas of inflammatory cell infiltration in the oxysterol-HFD-fed group. In in vitro experiments, addition of oxysterol (7-KC) to murine macrophages induced MCP-1 production but did not alter MMP secretion. The data from this study and an aforementioned study 18) are consistent with the idea that enhanced monocyte-mediated inflammation and the resulting increase in macrophage MMP activity can induce plaque destabilization and rupture.
Oxysterol measurements using gas-liquid chromatography mass spectrometry showed that dietary oxysterol intake resulted in an increase in liver oxysterol concentrations, but did not lead to an increase in plasma oxysterol concentrations. In contrast, immunohistochemical analysis showed an increase in oxysterols (7-KC) in monocyte-positive areas of the plaques, which was greater in the oxysterol-HFD-fed group than in the HFD-fed group. Interestingly, 7-KC appeared to co-localize with ApoB48 (a lipoprotein involved in lipid absorption in the small intestine). Because dietary oxysterols did not affect oxidized LDL/cholesterol ratios in the plasma, it is unlikely that oxysterols incorporated into LDL play a major role in the pathogenesis of plaque destabilization and rupture; therefore, these data suggest a major role for monocyte/macrophage accumulation of diet-derived oxysterols in causing plaque destabilization and rupture.
Another new finding of the present study was 
